Hyphens Pharma has launched Winlevi® (clascoterone) cream 1% in Singapore and Malaysia, marking the novel acne treatment’s first entry into Southeast Asia. The launch follows an exclusive licence and supply agreement with Cassiopea S.p.A., a subsidiary of Cosmo Pharmaceuticals, covering Winlevi® and its future product extensions across 10 Southeast Asian countries.
Winlevi® is the first new class of molecule in acne treatment in over 40 years. Its active ingredient, clascoterone, is the first commercially available topical androgen receptor inhibitor for acne, reducing sebum production and inflammation without systemic anti-androgen side effects. Since its initial US launch in 2021, it has become the most prescribed branded topical acne treatment in that market, with over 1.3 million prescriptions as of 2024.
Winlevi® is available via prescription through clinics and hospitals, with registration underway in other Southeast Asian markets and a progressive regional rollout planned. Hyphens Pharma has convened an Advisory Board of 12 dermatologists from Singapore, Malaysia, the Philippines and the US to support its integration into clinical practice.
